Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
|Articles|April 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 4
- Volume 16
- Issue 4
Eisai to Acquire Morphotek to Expand into Biologic Therapeutics
Eisai to Acquire Morphotek to Expand into Biologic Therapeutics
Advertisement
TOKYO, JapanEisai Co. Ltd and Eisai Corporation of North American (Woodcliff Lake, New Jersey) have signed a definitive agreement to acquire Morphotek (Exton, Pennsylvania) for $325 million. The acquisition is pending subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Morphotek develops therapeutic monoclonal antibodies and is evaluating two in early-stage clinical trials. Eisai's portfolio of oncology drugs currently includes small-molecule anticancer agents.
Articles in this issue
over 19 years ago
Curcumin Evaluated for the Treatment of Pancreatic Cancerover 19 years ago
Tykerb Approved for Metastatic HER2+ Breast Cancerover 19 years ago
Drug for BPH May Also Reduce the Risk of Prostate Cancerover 19 years ago
Phase III Trial of Prostvac-VF Is Launchedover 19 years ago
Electronic System Reminds Patients to Schedule Examsover 19 years ago
Phase II Trial of Panzem for Renal Cell Carcinoma Initiatedover 19 years ago
Chemotherapy May Enrich Tumorigenic Cells in Breast Caover 19 years ago
Watchful Waiting Management for Prostate Ca a Hard SellAdvertisement
Related to this article
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
3
Is Vitamin C an Epigenetic Interception Strategy in Pre-Leukemic Disease?
4
AI Foundation Models & Molecular Biomarkers in Breast Cancer
5